Parallel Advisors’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
Other funds holding NVCR
SCM
QCM
Parallel Advisors's NVCR Position: Q2 2026 in Review
Parallel Advisors increased its NovoCure (NVCR) stake by 244% in Q2 2026, buying an estimated $8.85K and bringing the position to 825 shares worth $12.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2837.
Parallel Advisors first reported a position in NVCR in Q1 2020 and has held it in 24 quarters since. The position peaked at $57K in Q1 2022. 217 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.
- Parallel Advisors held 825 shares of NovoCure worth $12.5K as of Q2 2026.
- Parallel Advisors bought 585 NovoCure shares in Q2 2026, an estimated $8.85K.
- NovoCure made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2837 holding.
- Parallel Advisors first reported a position in NovoCure in Q1 2020 and has held it in 24 quarters since.
- Parallel Advisors's NovoCure position peaked at $57K in Q1 2022.
- 217 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.
Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.